p.6 抽出テキスト

........................................................................................................................................................................ LEADER Lower Extremity Arterial Disease Event Reduction LPL Lipoprotein lipase Lp(a) Lipoprotein(a) mAb Monoclonal antibody MACE Major adverse cardiovascular events MESA Multi-Ethnic Study of Atherosclerosis MetS Metabolic syndrome MI Myocardial infarction mRNA Messenger RNA MTP Microsomal triglyceride transfer protein NAFLD Non-alcoholic fatty liver disease NNT Number needed to treat NPC1L1 Niemann-Pick C1-like protein 1 NSTE-ACS Non-ST elevation acute coronary syndrome o.d. Once a day (omni die) ODYSSEY Outcomes

Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab PAD Peripheral arterial disease PCI Percutaneous coronary intervention PCSK9 Proprotein convertase subtilisin/kexin type 9 PPAR-a Peroxisome proliferator-activated receptor-a PREDIMED Prevencion con Dieta Mediterranea PROCAM Prospective Cardiovascular Munster Study PROMINENT Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN PatiENts With DiabeTes PUFA Polyunsaturated fatty acid PURE Prospective Urban Rural Epidemiology RA Rheumatoid arthritis RCT Randomized controlled trial REDUCE-IT Reduction of Cardiovascular Events with EPA- Intervention Trial REVEAL Randomized EValuation of the Effects of Anacetrapib Through Lipid modification RR Relative risk RYR Red yeast rice SAMS Statin-associated muscle symptoms SBP Systolic blood pressure SCORE Systematic Coronary Risk Estimation SEAS Simvastatin and Ezetimibe in Aortic Stenosis SECURE-PCI Statins Evaluation in Coronary Procedures and Revascularization SFA Saturated fatty acid SHARP Study of Heart and Renal Protection siRNA Small interfering RNA SMI Severe mental illness SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels STAREE STAtin Therapy for Reducing Events in the Elderly STEMI ST-elevation myocardial infarction STRENGTH Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh CV Risk PatienTs with Hypertriglyceridemia TC Total cholesterol T1DM Type 1 diabetes mellitus T2DM Type 2 diabetes mellitus TGs Triglycerides TIA Transient ischaemic attack TIMI Thrombolysis In Myocardial Infarction TNF Tumour necrosis factor TNT Treating to New Targets TRL Triglyceride-rich lipoprotein ULN Upper limit of normal VA-HIT Veterans Affairs High Density Lipoprotein Intervention Trial VITAL VITamin D and OmegA-3 Trial VLDL Very low-density lipoprotein WHO World Health Organization WOSCOPS West of Scotland Coronary Prevention Study

1 Preamble

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate. A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC) and its partners such as European Atherosclerosis Society (EAS), as well as by other societies and organisations. Because of their impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (http://www.escardio.org/Guidelines-&-Education/ Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC- Guidelines). The ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated. The ESC carries out a number of registries which are essential to assess diagnostic/therapeutic processes, use of resources and adherence to Guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on data collected during routine clinical practice. The guidelines are developed together with derivative educational material addressing the cultural and professional needs for cardiologists and allied professionals. Collecting high-quality observational data, at appropriate time interval following the release of ESC Guidelines, will help evaluate the level of implementation of the Guidelines, checking in priority the key end points defined with the ESC Guidelines and Education Committees and Task Force members in charge. The Members of this Task Force were selected by the ESC and EAS, including representation from relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field from Downloaded from academic.oup.com/eurheartj/article/41/1/111/5556353 by guest on 07 October 2026